Literature DB >> 14684566

Helicobacter pylori infection and long term proton pump inhibitor therapy.

K E L McColl1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14684566      PMCID： PMC1773922          DOI： 10.1136/gut.53.1.5

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  26 in total

1.  Helicobacter pylori and reflux disease.

Authors:  K E McColl; D Gillen
Journal:  Lancet       Date:  2001-11-17       Impact factor: 79.321

2.  Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis.

Authors:  J Labenz; A L Blum; E Bayerdörffer; A Meining; M Stolte; G Börsch
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

3.  Helicobacter pylori infection and chronic gastric acid hyposecretion.

Authors:  E M El-Omar; K Oien; A El-Nujumi; D Gillen; A Wirz; S Dahill; C Williams; J E Ardill; K E McColl
Journal:  Gastroenterology       Date:  1997-07       Impact factor: 22.682

4.  Long term omeprazole therapy for reflux esophagitis:follow-up in serum gastrin levels,EC cell hyperplasia and neoplasia.

Authors:  Pankaj Singh; Anant Indaram; Ronald Greenberg; Vernu Visvalingam; Simmy Bank
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 5.  Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review.

Authors:  Anan Raghunath; A Pali S Hungin; David Wooff; Susan Childs
Journal:  BMJ       Date:  2003-04-05

6.  Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease.

Authors:  M Stolte; A Meining; J M Schmitz; T Alexandridis; E Seifert
Journal:  Aliment Pharmacol Ther       Date:  1998-03       Impact factor: 8.171

7.  The significance of cagA(+) Helicobacter pylori in reflux oesophagitis.

Authors:  V J Warburton-Timms; A Charlett; R M Valori; J S Uff; N A Shepherd; H Barr; C A McNulty
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

8.  Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group.

Authors:  L Lundell; P Miettinen; H E Myrvold; S A Pedersen; K Thor; A Andersson; J Hattlebakk; N Havu; E Janatuinen; K Levander; B Liedman; P Nyström
Journal:  Gastroenterology       Date:  1999-08       Impact factor: 22.682

9.  Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease.

Authors:  P Moayyedi; C Bardhan; L Young; M F Dixon; L Brown; A T Axon
Journal:  Gastroenterology       Date:  2001-11       Impact factor: 22.682

10.  Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole.

Authors:  E F Verdú; D Armstrong; J P Idström; J Labenz; M Stolte; G Dorta; G Börsch; A L Blum
Journal:  Gut       Date:  1995-12       Impact factor: 23.059
View more
  5 in total

Review 1.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

2.  Proton pump inhibitors have pH-dependent effects on the thermostability of the carboxyl-terminal domain of voltage-gated proton channel Hv1.

Authors:  Qing Zhao; Weiyan Zuo; Shangrong Zhang; Yongqiang Zhang; Chuanyong Li; Shu Jie Li
Journal:  Eur Biophys J       Date:  2017-09-09       Impact factor: 1.733

Review 3.  Maintenance therapy in gastro-oesophageal reflux disease.

Authors:  Miguel Bixquert
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Cost-effectiveness of six strategies for Helicobacter pylori diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern.

Authors:  Kyland P Holmes; John C Fang; Brian R Jackson
Journal:  BMC Health Serv Res       Date:  2010-12-21       Impact factor: 2.655

5.  Proton pump inhibitors and vascular function: A prospective cross-over pilot study.

Authors:  Yohannes T Ghebremariam; John P Cooke; Fouzia Khan; Rahul N Thakker; Peter Chang; Nigam H Shah; Kevin T Nead; Nicholas J Leeper
Journal:  Vasc Med       Date:  2015-04-02       Impact factor: 3.239
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.